A randomized, open-label study of the effect of Bondronat [ibandronic acid] compared with zoledronic acid on bone turnover, bone resorption, and bone formation in patients with metastatic bone disease from breast cancer.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Feb 2010

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibandronic acid (Primary) ; Zoledronic acid
Indications Advanced breast cancer; Cancer metastases
Focus Therapeutic Use
Sponsors Roche

Most Recent Events

16 Feb 2008 Status changed from in progress to completed.
20 Jun 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight